Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,819 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Parkinson Disease Clear all
Terminated Phase 2 Interventional Results available

Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

NCT02162979
View directory record Official record
Conditions
Parkinson's Disease
Interventions
sildenafil, Placebo
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 4 Interventional Results available

Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study

NCT00590122
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Parcopa, carbidopa-levodopa (Sinemet)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
31 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Jun 7, 2026, 9:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Parkinson's Diseases Susceptibility Genes and Pesticides

NCT00044590
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years and older
Enrollment
1,870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

NCT03482882
View directory record Official record
Conditions
Treatment of Depression in Adults With Parkinson's Disease (PD)
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Costa Mesa, California • Fountain Valley, California • Pasadena, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Jun 7, 2026, 9:24 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

PET Imaging in Parkinson Disease Dementia

NCT01052350
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 7, 2026, 9:24 AM EDT
Completed No phase listed Observational

Functional Magnetic Resonance Imaging (fMRI) During Deep Brain Stimulation (DBS) to Treat Parkinson's Disease

NCT01809613
View directory record Official record
Conditions
Parkinson Disease, Essential Tremor, Dystonia, Obsessive Compulsive Disorder
Interventions
Functional Magnetic Resonance Imaging (fMRI)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

NCT05064059
View directory record Official record
Conditions
Colorectal Cancer
Interventions
favezelimab/pembrolizumab, regorafenib, TAS-102
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 7, 2026, 9:24 AM EDT
Recruiting Not applicable Interventional

Endurance Exercise & Virtual Reality for Optimizing Cortical Excitability and Neuroplasticity in PD

NCT06133283
View directory record Official record
Conditions
Parkinson Disease
Interventions
High intensity endurance exercise, Stretching exercise, Virtual reality (VR)-based gaming
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 7, 2026, 9:24 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07216703
View directory record Official record
Conditions
Cervical Cancer
Interventions
Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin, Carboplatin, Rescue Medications
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
14
States / cities
Miami Beach, Florida • West Palm Beach, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 7, 2026, 9:24 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Intestinal Immunity in Neurologic Disease

NCT06329453
View directory record Official record
Conditions
Multiple Sclerosis, Parkinson Disease, REM Sleep Behavior Disorder
Interventions
Colon Tissue Biopsy
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
North Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Merging Yoga and Occupational Therapy for Parkinson Disease: Phase 2

NCT03578653
View directory record Official record
Conditions
Parkinson Disease
Interventions
Merging Yoga and Occupational Therapy for Parkinson disease
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

NCT03631407
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Vicriviroc, Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Scottsdale, Arizona • Encinitas, California • Fresno, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Not applicable Interventional

A Novel Balance Program to Improve Balance in People With Parkinson's Disease

NCT05906875
View directory record Official record
Conditions
Rehabilitation Exercise, Physical Therapy
Interventions
Lateral Stepping Exercise 1, Lateral Stepping Exercise 2, Lateral Stepping Exercise 3, Lateral Stepping Exercise 4, Lateral Stepping Exercise 5
Other
Lead sponsor
New York Institute of Technology
Other
Eligibility
50 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety Study of ADS-5102 in PD Patients With LID

NCT02202551
View directory record Official record
Conditions
Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease (PD)
Interventions
ADS-5102
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Not applicable Interventional Results available

Peer Partners to Improve Physical Activity in Older Latino and Latina Adults With Parkinson's Disease.

NCT06170866
View directory record Official record
Conditions
Parkinson Disease
Interventions
Socially supported physical activity
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jun 7, 2026, 9:24 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

NCT05357612
View directory record Official record
Conditions
Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis
Interventions
Pimavanserin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Not applicable Interventional Results available

Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

NCT02445651
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
Intravenous and Oral n-acetyl cysteine, Control group, Oral Supplements: Baicalin, Ganoderma, Omega 3 and Curcumin
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients

NCT00004451
View directory record Official record
Conditions
Parkinson Disease
Interventions
Glucose
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2005 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

NCT05642442
View directory record Official record
Conditions
Parkinson Disease, Tremor
Interventions
Placebo, Suvecaltamide
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Jun 7, 2026, 9:24 AM EDT
Terminated Phase 1Phase 2 Interventional

Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

NCT03116529
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Combination Radiation, Immunotherapy, Surgery
Combination Product
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Tucson, Arizona • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Jun 7, 2026, 9:24 AM EDT
Enrolling by invitation Not applicable Interventional

Connectomic Guided DBS for Parkinson's Disease

NCT06618157
View directory record Official record
Conditions
Parkinson Disease, Tremor, Dyskinesias
Interventions
Cerebellothalamic optimized deep brain stimulation, Pallidothalamic optimized deep brain stimulation, No deep brain stimulation, Usual care deep brain stimulation
Device · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 1Phase 2 Interventional

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

NCT04303169
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Vibostolimab, Gebasaxturev, MK-4830, Favezelimab + Pembrolizumab, ATRA
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Not applicable Interventional

Effects of Deep Brain Stimulation (DBS) Frequency on Neural Synchrony

NCT02304848
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DBS (Deep Brain Stimulation)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Jun 7, 2026, 9:24 AM EDT
Completed Phase 4 Interventional Results available

Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate

NCT04006925
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Parkinson Disease
Interventions
Sodium Oxybate, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jun 7, 2026, 9:24 AM EDT